Gland Pharma shares fell after a significant block deal involving Fosun Pharma Industrial. The company's VSEZ facility received zero USFDA observations after a recent inspection. Gland Pharma reported strong Q1FY27 results with increased profit and revenue. Its CDMO and B2B businesses showed substantial year-on-year growth. The pharma stock has gained significantly year-to-date.
Market Samachar is a news aggregator. This article was originally published by Stocks-Markets-Economic Times. Tap the button above to read the full story on their site.